Financing ·
Annovis prices $21M public offering of common stock and warrants at $1.00 per unit
ANVSAnnovis Bio, Inc.
Annovis Bio priced a public offering of 19,000,000 shares of common stock and accompanying warrants to purchase up to 21,000,000 additional shares. The company also issued pre-funded warrants for up to 2,000,000 shares in lieu of common stock for certain investors. Each unit consisting of a share (or pre-funded warrant) and an accompanying warrant was priced at $1.00 ($0.9999 for the pre-funded warrant units). Gross proceeds are expected to be approximately $21.0 million, before deducting underwriting discounts and offering expenses. The offering closed on November 6, 2026, with net proceeds intended for the clinical development of lead compound buntanetap for Alzheimer’s and Parkinson’s diseases, as well as working capital. Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases.